Return Of Anti-commercial Bribery Campaign In China Could Benefit Big Companies And Blacklist Others
This article was originally published in PharmAsia News
SHANGHAI - Last month, China's Ministry of Health released a notice urging local health authorities to crack down on kickbacks to doctors in return for sales of pharmaceutical products under a policy that would ban drug manufacturers from participating in drug tenders in public hospitals for two years if they are blacklisted
You may also be interested in...
The recent clampdown on commercial bribery, highlighted by the GSK case, and a new drug cost survey from NDRC could indicate drug pricing reform in China, experts say.
Banned two years ago, second-round drug price negotiations may be making a comeback in China, and the impact could be far-reaching for pharma companies.
China's Generic Companies Leaning Toward Innovation To Target Global Market: FT China Healthcare And Life Science Summit
SHANGHAI - While China reported a slowdown of its economic growth in the second quarter - 10.3 percent compared to 11.9 percent in the same year-ago quarter - many economists feared China was close to overheating, but the life science industry in China is still hot to global investors, and Chinese generics companies are evolving to become more integrated and innovative, according to speakers from the FT China Healthcare and Life Science Summit held in Shanghai July 13